Esperion Therapeutics Inc.

NASDAQ:ESPR   3:59:56 PM EDT
3.72
-0.21 (-5.34%)
4:39:24 PM EDT: $3.73 +0.01 (+0.27%)
Other Pre-Announcement

Esperion Provides Preliminary Fourth Quarter 2021 Financial Results

Published: 01/11/2022 14:09 GMT
Esperion Therapeutics Inc. (ESPR) - Esperion Provides Preliminary Fourth Quarter 2021 Financial Results and Clear Outcomes Program Update.
Esperion Therapeutics Inc - Fourth-quarter 2021 U.S. Net Product Revenue Estimated Between $12.0 Million to $12.5 Million.
Esperion Therapeutics Inc - Reiterates Full-year 2022 Operating Expense Guidance of $220 Million to $240 Million.